This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Trevena’s 8K filing here.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
See Also
- Five stocks we like better than Trevena
- What Are Earnings Reports?
- How to Invest in Small Cap Stocks
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- These Are the Dividend Stocks Insiders Bought in January
- What is the Australian Securities Exchange (ASX)
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
